All News
German Society of Rheumatology COVID Pandemic Recommendations
The Annals of Rheumatic Disease has published the preliminary recommendations of the German Society of Rheumatology for the management of Inflammatory rheumatic diseases patients during the SARS-CoV-2/Covid-19 pandemic.
These preliminary recommendations are based on an expert consensus from 17 experienced German rheumatologists.
IL-6 Inhibitors May Benefit COVID-19 Infection
In the last few days there have been encouraging "preliminary" reports that IL-6 inhibition by either tocilizumab or sarilumab may be efficacious in patients with severe coronavirus infections.
High Dose Chloroquine Harmful in Severe COVID-19
JAMA Open Network reports an interim analysis of the Brazilian CloroCovid-19 trial showing thta higher doses of chloroquine (CQ) in the treatment of severe COVID-19 was associated with QTc interval prolongation and increased mortality.
Read ArticleFDA Consumer Warnings on Cannabis and CBD
The FDA issued a new consumer update on what you need to know about Cannabis or Cannabis-derived Compounds, Including CBD. This is part of the FDA effort to answer questions about the science, safety, and quality of products containing cannabis and cannabis-derived compounds, particularly CBD.
Read ArticleLower Risk of Diabetes with Abatacept
Patients with rheumatoid arthritis (RA) treated with abatacept (Orencia) had a lower risk of developing diabetes mellitus compared with those receiving certain tumor necrosis factor (TNF) inhibitors, a large cohort study suggested.
Read ArticleACR COVID-19 Guidance for Rheumatic Disease Patients
On April 11th, the ACR Board of Directors approved a COVID-19 guidance document written by an ACR task force charged with updating and clarifying recommendations for rheumatologists and rheumatic disease patient management during the current COVID-19 crisis.
Read ArticleGuselkumab a Hit in Phase III for PsA
The monoclonal antibody guselkumab (Tremfya), which binds the interleukin (IL)-23 p19 subunit, was effective for psoriatic arthritis in two large clinical trials, providing comprehensive benefits for this heterogeneous disorder, investigators reported in The Lancet.
Read ArticleTNR - Grand Rounds: Safety of Biologics & New Agents
On Tuesday, April 7th, RheumNow hosted its first Tuesday Nite Rheumatology webinar - kicking off a two-month series of Rheumatology Grand Rounds lectures. The first session featured Jack Cush, MD (UT Southwestern) who lectured on "The Safety of Biologics and Newer Agents".
Read ArticleNICE Guidelines on Managing Rheumatologic Conditions During COVID-19 Pandemic
On April 3rd, the National Institute for Health and Care Excellence (NICE) in the UK, published a rapid guideline for managing children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection.
Read ArticleRheumNow Podcast – Pandemic Numbers (4.3.20)
Dr. Jack Cush reviews the news on COVID-19 and FDA actions this past week. Be sure to check out:
Read ArticleCDC: Impact of Underlying Health Conditions Among COVID-19 Patients
The March 31 release of the Morbidity and Mortality Weekly Report (MMWR) reviews the impact of several key comorbidities, most commonly diabetes mellitus, chronic lung disease, and cardiovascular disease, as cofactors leading to worse outcomes with COVID-19 infections. Below are e
Read ArticleRheumNow Podcast – New World Order (3.27.20)
Dr. Jack Cush reviews the news and COVID developments from this past week.
Read ArticleACR Infusion Guidance During COVID-19 Crisis
The American College of Rheumatology (ACR) has published a guidance document on infusions and office based therapies.
Read ArticleDr. Artie Kavanaugh - Don't Stop!
Drs. Cush and Kavanaugh discuss the downside of stopping hydroxychloroquine, DMARDs and biologics in lupus, RA and pregnancy.
Read Article
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)


